AmpliSeq Childhood Cancer Panel

Overview

Illumina AmpliSeq targeted DNA sequencing panel covering 130 cancer-relevant genes curated for pediatric malignancies; used for variant screening in cell lines and tumor models.

Used by

• Applied to three independent heMSC lines in the Ewing sarcoma cell-of-origin study to confirm absence of pathogenic cooperating mutations; no variants detected, establishing that EWS::FLI1 expression alone is sufficient to drive the Ewing-like transcriptional program and in vivo tumorigenesis. PMID:25186949

Notes

• 130-gene panel; excludes most of the exome — cryptic cooperating mutations outside the panel cannot be ruled out by this assay alone.
• Used here as a negative-result screen to support the single-oncogene transformation model.

Sources

This page was processed by entity-page-writer on 2026-05-11.